Suman Drugs Private Limited
Pharmaceutical company specializing in manufacturing, importing, and exporting containers and components for drugs.
2000 | HabsigudaHyd-7., Telangana (India) | Active
Suman Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.90 M
- Paid Up Capital ₹ 0.10 M
- Company Age 24 Year, 2 Months
- Last Filing with ROC 31 Mar 2011
- Open Charges ₹ 3.00 M
About Suman Drugs
Suman Drugs Private Limited (SDPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 December 2000 and has a history of 24 years and two months. Its registered office is in Habsiguda,Hyd-7., Telangana.
The Company is engaged in the Packaging Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2011. It's a company limited by shares with an authorized capital of Rs 0.90 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.00 M.
Padma Tallam and Prakash Linga serve as directors at the Company.
Company Details
- Location Habsiguda,Hyd-7., Telangana
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231TG2000PTC035808
- Company No.
035808
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Dec 2000
- Date of AGM
29 Sep 2011
- Date of Balance Sheet
31 Mar 2011
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Packaging
Who are the key members and board of directors at Suman Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Padma Tallam  | Director | 04-Dec-2000 | Current |
| Prakash Linga | Director | 04-Dec-2000 | Current |
Financial Performance of Suman Drugs.
Enhance accessibility to Suman Drugs's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Suman Drugs?
Unlock access to Suman Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
Open Charges
₹3.00 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- Punjab National Bank : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Oct 2002 | Punjab National Bank | ₹3.00 M | Open |
How Many Employees Work at Suman Drugs?
Unlock and access historical data on people associated with Suman Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Suman Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Suman Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.